Meridian Small Cap Growth Fund, under the guidance of ArrowMark Partners, released its investor letter for the second quarter of 2026, detailing the robust performance of the U.S. market. The period witnessed a substantial market upswing, driven by a reduction in global tensions, declining oil prices, and strong corporate financial results. Technology and healthcare growth stocks were at the forefront of this rally, with significant contributions from AI-related investments. Despite these favorable conditions, the Meridian Small Cap Growth Fund's returns of 21.54% slightly trailed its benchmark, the Russell 2000 Growth Index, which achieved 25.71%. This discrepancy was primarily due to the fund's strategic focus on lower-volatility, quality businesses, which underperformed compared to the surging high-beta and momentum stocks. The fund maintains its commitment to high-quality enterprises, robust risk management, and safeguarding against market downturns, with portfolio adjustments being strategic rather than reactive to individual stock weaknesses.

Among its notable holdings, Veracyte, Inc. (NASDAQ: VCYT), a global leader in diagnostic solutions, played a key role in the fund's performance during this quarter. Veracyte's shares saw a significant increase, closing at $55.71 per share with a market capitalization of $4.44 billion by July 29, 2026. While experiencing a slight one-month dip of 2.40%, the company's shares demonstrated impressive resilience, gaining 136.96% over the past 52 weeks. The company's genomic diagnostics, particularly its Decipher prostate cancer test and Afirma thyroid test, are recognized for their strong proprietary clinical backing and long-term competitive edge. Future growth is anticipated from upcoming product introductions, including Prosigna for breast cancer and the TrueMRD platform for bladder cancer, alongside a consistent stream of clinical data reinforcing its multi-year expansion potential.

Veracyte's Strong Financial Performance and Strategic Growth

Veracyte (VCYT) has demonstrated remarkable financial strength, characterized by an upward revision in its financial forecasts and an earnings report that surpassed expectations. This performance is largely attributed to the robust demand for its established genomic diagnostic products, particularly the Decipher prostate cancer test and the Afirma thyroid test. The company's strategic focus on clinical evidence generation has fortified its market position, creating a significant competitive advantage in the diagnostics industry. The consistent double-digit volume growth observed in Decipher, coupled with enhanced performance from Afirma following workflow improvements, underscores Veracyte's operational efficiency and market penetration. These developments have not only boosted investor confidence but also validated the company's long-term growth strategy.

The company's impressive growth trajectory is further supported by an expanding portfolio of innovative diagnostic solutions. Veracyte's upcoming launches, including Prosigna for breast cancer and the TrueMRD platform for bladder cancer, are poised to open new revenue streams and broaden its market reach. These new offerings, combined with a steady pipeline of clinical data, are critical in sustaining Veracyte's multi-year growth runway. The successful integration of these advanced diagnostics into clinical practice is expected to drive continued volume growth and enhance the company's profitability. Furthermore, the strategic emphasis on durable, volume-driven testing revenue, coupled with a commitment to evidence-based diagnostics, positions Veracyte as a resilient and innovative leader in the global diagnostic landscape.

Meridian Fund's Strategic Investment in Growth and Quality

Meridian Small Cap Growth Fund's investment philosophy, managed by ArrowMark Partners, prioritizes quality businesses with strong growth potential while maintaining a focus on risk management and downside protection. Despite the broader market's strong rally in Q2 2026, which saw high-beta and momentum stocks outperform, the fund's deliberate focus on lower-volatility, quality-oriented holdings led to a slight underperformance compared to its benchmark. This strategic choice reflects a commitment to long-term value creation over short-term speculative gains. The fund's portfolio adjustments are driven by careful strategic allocation rather than reactive responses to individual stock fluctuations, emphasizing a disciplined approach to investment.

The fund's positive contribution from Veracyte, Inc. (VCYT) highlights its ability to identify and invest in companies with strong fundamentals and promising futures. Veracyte's genomic diagnostics, built on extensive clinical evidence, align perfectly with the fund's criteria for durable revenue and defensible competitive advantages. The fund's continued confidence in Veracyte, even amidst market shifts, demonstrates its belief in the company's intrinsic value and its potential for sustained growth. By focusing on businesses that offer expanding product menus and clear growth runways, Meridian Small Cap Growth Fund aims to deliver consistent returns while mitigating risks, ensuring a balanced and robust investment strategy for its shareholders.